Cargando…

Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects()

Prophylactic vaccines for human papillomavirus (HPV) are being introduced in many countries for the prevention of cervical cancer, the second most important cause of cancer-related death in women globally. This is likely to have a significant impact on the future burden of cervical cancer, particula...

Descripción completa

Detalles Bibliográficos
Autores principales: Wigle, Jannah, Coast, Ernestina, Watson-Jones, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763375/
https://www.ncbi.nlm.nih.gov/pubmed/23777956
http://dx.doi.org/10.1016/j.vaccine.2013.06.016
_version_ 1782283002644004864
author Wigle, Jannah
Coast, Ernestina
Watson-Jones, Deborah
author_facet Wigle, Jannah
Coast, Ernestina
Watson-Jones, Deborah
author_sort Wigle, Jannah
collection PubMed
description Prophylactic vaccines for human papillomavirus (HPV) are being introduced in many countries for the prevention of cervical cancer, the second most important cause of cancer-related death in women globally. This is likely to have a significant impact on the future burden of cervical cancer, particularly where screening is non-existent or limited in scale. Previous research on the challenges of vaccinating girls with the HPV vaccine has focused on evidence from developed countries. We conducted a systematic search of the literature in order to describe the barriers and challenges to implementation of HPV vaccine in low- and middle-income countries. We identified literature published post-2006 to September 2012 from five major databases. We validated the findings of the literature review with evidence from qualitative key informant interviews. Three key barriers to HPV vaccine implementation were identified: sociocultural, health systems and political. A linked theme, the sustainability of HPV vaccines programmes in low- and middle-income countries, cuts across these three barriers. Delivering HPV vaccine successfully will require multiple barriers to be addressed. Earlier research in developed countries emphasised sociocultural issues as the most significant barriers for vaccine roll-out. Our evidence suggests that the range of challenges for poorer countries is significantly greater, not least the challenge of reaching girls for three doses in settings where school attendance is low and/or irregular. Financial and political barriers to HPV vaccine roll-out continue to be significant for many poorer countries. Several demonstration and pilot projects have achieved high rates of acceptability and coverage and lessons learned should be documented and shared.
format Online
Article
Text
id pubmed-3763375
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-37633752013-09-09 Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects() Wigle, Jannah Coast, Ernestina Watson-Jones, Deborah Vaccine Review Prophylactic vaccines for human papillomavirus (HPV) are being introduced in many countries for the prevention of cervical cancer, the second most important cause of cancer-related death in women globally. This is likely to have a significant impact on the future burden of cervical cancer, particularly where screening is non-existent or limited in scale. Previous research on the challenges of vaccinating girls with the HPV vaccine has focused on evidence from developed countries. We conducted a systematic search of the literature in order to describe the barriers and challenges to implementation of HPV vaccine in low- and middle-income countries. We identified literature published post-2006 to September 2012 from five major databases. We validated the findings of the literature review with evidence from qualitative key informant interviews. Three key barriers to HPV vaccine implementation were identified: sociocultural, health systems and political. A linked theme, the sustainability of HPV vaccines programmes in low- and middle-income countries, cuts across these three barriers. Delivering HPV vaccine successfully will require multiple barriers to be addressed. Earlier research in developed countries emphasised sociocultural issues as the most significant barriers for vaccine roll-out. Our evidence suggests that the range of challenges for poorer countries is significantly greater, not least the challenge of reaching girls for three doses in settings where school attendance is low and/or irregular. Financial and political barriers to HPV vaccine roll-out continue to be significant for many poorer countries. Several demonstration and pilot projects have achieved high rates of acceptability and coverage and lessons learned should be documented and shared. Elsevier Science 2013-08-20 /pmc/articles/PMC3763375/ /pubmed/23777956 http://dx.doi.org/10.1016/j.vaccine.2013.06.016 Text en © 2013 The Authors https://creativecommons.org/licenses/by/3.0/ Open Access under CC BY 3.0 (https://creativecommons.org/licenses/by/3.0/) license
spellingShingle Review
Wigle, Jannah
Coast, Ernestina
Watson-Jones, Deborah
Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects()
title Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects()
title_full Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects()
title_fullStr Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects()
title_full_unstemmed Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects()
title_short Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects()
title_sort human papillomavirus (hpv) vaccine implementation in low and middle-income countries (lmics): health system experiences and prospects()
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763375/
https://www.ncbi.nlm.nih.gov/pubmed/23777956
http://dx.doi.org/10.1016/j.vaccine.2013.06.016
work_keys_str_mv AT wiglejannah humanpapillomavirushpvvaccineimplementationinlowandmiddleincomecountrieslmicshealthsystemexperiencesandprospects
AT coasternestina humanpapillomavirushpvvaccineimplementationinlowandmiddleincomecountrieslmicshealthsystemexperiencesandprospects
AT watsonjonesdeborah humanpapillomavirushpvvaccineimplementationinlowandmiddleincomecountrieslmicshealthsystemexperiencesandprospects